Host |
Mouse |
Klon |
SEN28 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thymus |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM096 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM51 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Thymus. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
1 ml |
Concentrate |
CE/IVD |
Z2391ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM51 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Thymus. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
7 ml |
Ready-to-use |
CE/IVD |
Z2391MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM51 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Thymus. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
0.5 ml |
Concentrate |
CE/IVD |
Z2391MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM51 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Thymus. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
0.1 ml |
Concentrate |
CE/IVD |
Z2391MT |
-
|
Host |
Mouse |
Klon |
T2H5 |
Format |
Purified |
Methode |
P, F, WB, IP, EL |
Vorbehandlung |
Citrate oder Trypsin |
Positivkontrolle |
Human tonsil |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native purified protein from human mammary tumour |
Tenascin
|
Zytomed Systems GmbH |
T2H5 |
200 µg (200 µl) |
Purified |
RUO |
620-0072 |
-
|
Host |
Mouse |
Klon |
DB7 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil, appendix |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG2a |
Lokalisation |
Extracellular |
Tenascin C (TNC)
|
Zytomed Systems GmbH |
DB7 |
0.5 ml |
Concentrate |
RUO |
MSK104-05 |
-
|
Host |
Rabbit |
Klon |
ZR365 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Testis |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human TFE3 protein |
Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
7 ml |
Ready-to-use |
CE/IVD |
Z2605RP |
-
|
Host |
Rabbit |
Klon |
ZR365 |
Format |
concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Testis |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human TFE3 protein |
Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
0.1 ml |
concentrate |
CE/IVD |
Z2605RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Pepsin or Trypsin |
Positivkontrolle |
Small Intestine |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of the precursor form of human TGFβ3. |
Lokalisation |
Cytoplasm |
TGF beta III (Transforming Growth Factor)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-3944 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM105 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
1 ml |
Concentrate |
CE/IVD |
Z2416ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM105 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
7 ml |
Ready-to-use |
CE/IVD |
Z2416MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM105 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
0.5 ml |
Concentrate |
CE/IVD |
Z2416MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM105 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human thrombomodulin protein fragment (aa69-194) |
Lokalisation |
Cytoplasm |
Thrombomodulin
|
Zeta Corporation |
ZM105 |
0.1 ml |
Concentrate |
CE/IVD |
Z2416MT |
-
|
Host |
Mouse |
Klon |
A6.1 |
Format |
Concentrate |
Methode |
F, P, IF, IP, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
1 ml |
Concentrate |
CE/IVD |
MOB315 |
-
|
Host |
Mouse |
Klon |
A6.1 |
Format |
Concentrate |
Methode |
F, P, IF, IP, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB315-01 |
-
|
Host |
Mouse |
Klon |
A6.1 |
Format |
Concentrate |
Methode |
F, P, IF, IP, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Secretory Granules, Golgi Complex, Endoplasmic Reticulum |
Thrombospondin (TSP)
|
Diagnostic Biosystems |
A6.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB315-05 |
-
|
Host |
Mouse |
Klon |
P-GF.44C |
Format |
Concentrate |
Methode |
F, P, WB |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Thymidine Phosphorylase
|
Diagnostic Biosystems |
P-GF.44C |
1 ml |
Concentrate |
CE/IVD |
MOB292 |
-
|
Host |
Mouse |
Klon |
P-GF.44C |
Format |
Concentrate |
Methode |
F, P, WB |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Thymidine Phosphorylase
|
Diagnostic Biosystems |
P-GF.44C |
0.1 ml |
Concentrate |
CE/IVD |
MOB292-01 |
-
|
Host |
Mouse |
Klon |
P-GF.44C |
Format |
Concentrate |
Methode |
F, P, WB |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Thymidine Phosphorylase
|
Diagnostic Biosystems |
P-GF.44C |
0.5 ml |
Concentrate |
CE/IVD |
MOB292-05 |
-
|
Host |
Rabbit |
Klon |
SP112 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon Carcinoma, tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near C-terminus of human TS |
Lokalisation |
Cytoplasm, nucleus |
Thymidylate Synthase (TS)
|
Zytomed Systems GmbH |
SP112 |
1 ml |
Concentrate |
RUO |
520-4124 |
-
|
Host |
Mouse |
Klon |
TS106 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
5-FU resistant cancer. |
Verdünnung |
1:50 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human thymidylate synthase |
Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
1 ml |
Concentrate |
CE/IVD |
Z2199ML |
-
|
Host |
Mouse |
Klon |
TS106 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
5-FU resistant cancer. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human thymidylate synthase |
Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
7 ml |
Ready-to-use |
CE/IVD |
Z2199MP |
-
|
Host |
Mouse |
Klon |
TS106 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
5-FU resistant cancer. |
Verdünnung |
1:50 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human thymidylate synthase |
Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
0.5 ml |
Concentrate |
CE/IVD |
Z2199MS |
-
|
Host |
Mouse |
Klon |
TS106 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
5-FU resistant cancer. |
Verdünnung |
1:50 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human thymidylate synthase |
Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
0.1 ml |
Concentrate |
CE/IVD |
Z2199MT |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
1 ml |
Concentrate |
CE/IVD |
MOB223 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB223-01 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB223-05 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Thyroid |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM576 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Thyroid |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
25 ml |
Ready-to-use |
CE/IVD |
PDM576-25 |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
1ml |
Concentrate |
CE/IVD |
Z2062ML |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
- |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2062MP |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2062MS |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2062MT |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
1 ml |
Concentrate |
CE/IVD |
MOB418 |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.1 ml |
Concentrate |
CE/IVD |
MOB418-01 |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.5 ml |
Concentrate |
CE/IVD |
MOB418-05 |
-
|
Host |
Rabbit |
Klon |
SP141 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
IHC-P |
Vorbehandlung |
Citrate pH 6 |
Positivkontrolle |
Thyroid |
Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
0.5 ml |
Concentrate |
RUO |
520-4412 |
-
|
Host |
Rabbit |
Klon |
SP141 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
IHC-P |
Vorbehandlung |
Citrate pH 6 |
Positivkontrolle |
Thyroid |
Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
1 ml |
Concentrate |
RUO |
520-4414 |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
7 ml |
Ready-to-use |
CE/IVD |
ALI130G7 |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
AVI130G |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.1 ml |
Concentrate |
CE/IVD |
CM130A |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.5 ml |
Concentrate |
CE/IVD |
CM130B |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
1 ml |
Concentrate |
CE/IVD |
CM130C |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
PM130AA |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2183ML |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2183MP |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2183MS |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2183MT |
-
|
Host |
Rabbit |
Klon |
ZR284 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length of human TIA-1 protein |
Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
1 ml |
Concentrate |
CE/IVD |
Z2599RL |
-
|